Condiciones de salud que Niacina (vitamina B3) puede ayudar a apoyar.
Topical niacinamide (4–5%) has been studied in multiple clinical trials for acne vulgaris, demonstrating anti-inflammatory and sebum-regulating effects. A controlled trial found 4% niacinamide gel to be comparably effective to 1% clindamycin gel, with the advantage of not promoting antibiotic resistance. A 2017 PubMed review found that 6 of 8 studies using topical nicotinamide showed significant acne reduction versus baseline or standard care.
Niacin is the dietary precursor to NAD+ and NADP+, coenzymes that are central to cellular antioxidant defense, including the regeneration of glutathione and support of antioxidant enzyme activity (SOD, catalase, GPx). Supplementation restores the cellular NAD+ pool, attenuates oxidative stress, and has been confirmed in animal and human mechanistic studies to enhance antioxidant enzyme activity.
Animal studies from the 1970s–80s established that niacinamide binds to benzodiazepine receptors with mild anxiolytic-like effects. Case series and clinical observations have suggested reduced anxiety in some individuals taking high-dose niacinamide. Evidence remains largely preclinical and case-based; large-scale RCTs are absent, but biological plausibility is documented in the literature.
Niacin (nicotinic acid) at pharmacologic doses (1,500–3,000 mg/day) raises HDL-C by up to 35%, reduces triglycerides and LDL-C, and reduces lipoprotein(a), directly addressing atherogenic lipid burden on arterial walls. Niacin also improves FMD and reduces carotid intima-media thickness in clinical trials. It has been used for arterial and lipid-related conditions since the 1950s.
A 12-week double-blind placebo-controlled RCT in 72 osteoarthritis patients found that niacinamide (3000 mg/day) improved global arthritis impact by 29% versus a 10% worsening in the placebo group (p=0.04), increased joint mobility by 4.5 degrees, reduced ESR by 22%, and allowed a 13% reduction in anti-inflammatory drug use. Observational data also associate higher niacin intake with lower prevalence of rheumatoid arthritis.
An uncontrolled case series of 74 consecutive Bell's palsy patients treated with oral or intramuscular niacin (100–250 mg) found good-to-excellent facial nerve response in nearly all cases within 2–4 weeks. Niacin's vasodilatory effect is proposed to improve microcirculation within the facial nerve canal, promoting recovery. This evidence dates to Kime's 1958 report and remains the primary dataset.
Nicotinic acid (niacin) has been shown to lower systolic and diastolic blood pressure in hyperlipidemic patients, with evidence from post-hoc analyses of large trials including the Coronary Drug Project. The mechanism may involve prostaglandin-mediated vasodilation independent of lipid effects. Both immediate- and extended-release forms have shown dose-dependent BP-lowering effects.
Nicotinic acid (high-dose niacin) is well-documented to raise blood glucose and HbA1c in patients with type 2 diabetes and dyslipidemia, representing an adverse metabolic effect at pharmacological doses. In contrast, niacinamide at physiological to moderate doses has not consistently shown problematic glucose effects and has been studied for potential beta-cell protection in type 1 diabetes prevention. The relationship is therefore bidirectional and form/dose-dependent.
Niacin (Vitamin B3) is the dietary precursor to NAD+ and NADH, the central coenzymes for over 500 enzymatic reactions including glycolysis, the TCA cycle, and oxidative phosphorylation. Supplementation in mitochondrial disease raises cellular NAD concentrations up to 24-fold and enhances Complex I substrate availability for ATP production.
Niacin (vitamin B3 as nicotinic acid) is an essential B vitamin for energy metabolism with IOM-established RDAs for children. NIH ODS-funded label analysis found niacin among the core nutrients at or above RDA in most children's MVMs, though it carries a risk of exceeding the UL in some products.
Niacin (nicotinic acid) raises HDL-C, reduces triglycerides, and modestly lowers LDL-C. It inhibits diacylglycerol acyltransferase-2 and increases hepatic apoB degradation. Despite the AIM-HIGH trial showing no added cardiovascular benefit when combined with statins, niacin remains used in dyslipidemia management for statin-intolerant patients.
Niacin (Vitamin B3) is a precursor to NAD+ and NADH, which are central to mitochondrial electron transport and ATP production. EFSA authorizes a health claim for niacin contributing to normal energy-yielding metabolism and reduction of tiredness and fatigue. Deficiency (pellagra) causes severe fatigue and weakness.
A 2024 systematic review and meta-analysis of 15 RCTs (European Journal of Nutrition) found that niacin supplementation significantly reduced CRP levels (SMD: -0.88, p=0.003) and TNF-α, indicating a meaningful anti-inflammatory effect. Niacin acts on the GPR109A receptor on immune cells, suppressing NF-κB signaling and pro-inflammatory cytokine production.
Niacin (nicotinic acid) at doses causing the 'niacin flush' produces clinically significant peripheral vasodilation through prostaglandin D2 and E2-mediated mechanisms. The flush represents genuine skin microvascular blood flow enhancement. Lower doses of immediate-release niacin (100–500 mg) can improve peripheral circulation and skin microvascular blood flow. High-dose niacin raises HDL and improves lipid profiles, indirectly supporting vascular health.
Dietary niacin intake has been associated with reduced risk of Alzheimer's disease and cognitive decline in observational studies (Journal of Neurology, Neurosurgery & Psychiatry). NAD+ levels decline with age, and niacin/nicotinamide precursors are being investigated in clinical trials for Alzheimer's disease and age-related cognitive impairment. Preclinical models showed cognitive protection; human RCTs remain preliminary.
Observational and cross-sectional research has found that patients with depression have significantly lower circulating nicotinamide (vitamin B3) levels than healthy controls, with moderate-to-large effect sizes. A 2023 Nutrients meta-analysis linked higher B-vitamin intake including niacin to lower depression prevalence. Mechanistically, niacin participates in tryptophan-serotonin metabolism; deficiency can reduce serotonin availability.
Niacin deficiency itself causes pellagra dermatitis; beyond deficiency correction, topical and oral niacinamide have been studied for atopic dermatitis and seborrheic dermatitis. Topical niacinamide stabilizes the epidermal barrier, reduces transepidermal water loss, and exerts anti-inflammatory effects relevant to eczematous conditions. A 2004 PubMed review confirmed anti-inflammatory effects in irritant and inflammatory skin conditions.
Niacin (vitamin B3) is the precursor to NAD+ and NADP+, coenzymes essential for hundreds of metabolic reactions including glycolysis, the TCA cycle, and oxidative phosphorylation. Niacin deficiency (pellagra) causes profound fatigue. EFSA authorizes the health claim that niacin contributes to normal energy-yielding metabolism.
Multiple epidemiological studies from the US and South Korea have found that higher dietary niacin intake is associated with a lower prevalence of open-angle glaucoma, independent of IOP. A 2025 non-randomized clinical trial in 58 POAG patients found 6 months of 500 mg/day oral niacinamide significantly improved quality of life scores and reduced intraocular pressure in both eyes. The mechanism involves neuroprotection of retinal ganglion cells via NAD+ replenishment.
Niacin (vitamin B3) is the precursor to NAD+ and NADP+, coenzymes central to energy metabolism and sirtuin-mediated aging pathways. NAD+ declines with age, and niacin/nicotinamide supplementation has been used as a foundational strategy to support NAD+ levels. Clinical evidence supports niacin for cardiovascular health and inflammatory control relevant to aging.
Vitamin B3 (niacin/nicotinic acid) is a water-soluble B-vitamin that is converted to NAD+ and NADP+, coenzymes essential for energy metabolism, DNA repair, and cell signaling in all growing tissues. Severe deficiency causes pellagra, which includes growth retardation and dermatitis. It is a required nutrient in all major infant formula standards and pediatric nutritional guidelines for healthy growth and development.
Niacin (vitamin B3) promotes cochlear blood flow via vasodilation and is a NAD+ precursor. Research from Weill Cornell Medical College showed that its derivative nicotinamide riboside prevents noise-induced damage to cochlear nerve synapses. Niacin has historically been used for sudden hearing loss and tinnitus via vasodilatory effects. A 2024 Stanford review confirmed vitamin B3 protects cochlear structures.
Niacin (vitamin B3) has an extensively studied but complex and evolving relationship with heart health. High-dose nicotinic acid robustly raises HDL cholesterol and lowers LDL cholesterol and triglycerides, and early trials showed cardiovascular benefit. However, two large modern RCTs (AIM-HIGH and HPS2-THRIVE) found no incremental reduction in cardiovascular events when niacin was added to statin therapy, and recent research identifies a niacin metabolite (4PY) as a potential promoter of vascular inflammation. High-dose niacin is no longer routinely recommended for cardiovascular risk reduction.
Topical niacinamide inhibits the transfer of melanosomes from melanocytes to keratinocytes, the primary cellular mechanism driving skin pigmentation. Multiple clinical trials, including a 12-week randomized double-blind split-face study in 50 women, demonstrated that 5% topical niacinamide significantly reduced hyperpigmented spots compared with vehicle control. Clinical use covers conditions including melasma, post-inflammatory hyperpigmentation, and age spots.
Niacin (vitamin B3) is a precursor to NAD+ and NADH, coenzymes essential for neuronal energy metabolism, DNA repair, and neuroprotection. Higher niacin intake is associated with reduced risk of cognitive decline in epidemiological studies. Niacin supplementation supports brain energy production and has been explored for cognitive and neuroprotective applications.
Niacin (vitamin B3) is a precursor to NAD+/NADH, coenzymes central to cellular energy metabolism and neuronal function. EU authorized health claims recognize niacin's contribution to normal psychological function, reduction of tiredness, and energy-yielding metabolism.
Niacin (vitamin B3) directly targets the atherogenic dyslipidemia that defines metabolic syndrome—elevated triglycerides, low HDL-cholesterol, and small dense LDL particles—through several established lipid-modulating mechanisms. Multiple randomized controlled trials in metabolic syndrome populations document significant improvements in HDL-C, triglycerides, and lipoprotein subfractions. A key limitation is that niacin can worsen insulin resistance, a core feature of metabolic syndrome, and large cardiovascular outcome trials (AIM-HIGH, HPS2-THRIVE) failed to demonstrate reduced cardiovascular events when niacin was added to statin therapy.
Vitamin B3 (niacin) is a foundational component of cellular metabolism, serving as the biosynthetic precursor to NAD+ and NADP+—coenzymes that drive oxidation-reduction reactions across glycolysis, the TCA cycle, fatty acid oxidation, and amino acid metabolism. At pharmacological doses, nicotinic acid also directly modulates lipid metabolism by inhibiting hepatic triglyceride synthesis and altering HDL/LDL profiles. The evidence base is robust, spanning biochemical characterization, human clinical trials, and systematic reviews involving thousands of participants.
Niacin (vitamin B3) has a historical basis in migraine treatment; high-dose niacin causes vasodilation via prostaglandin release. A large UK Biobank prospective study found low B3 intake had among the strongest correlations with migraine risk. Inositol nicotinate (flush-free niacin) has also been studied in headache contexts.
Niacin (nicotinic acid, vitamin B3) is a direct precursor to NAD⁺ and NADH, the primary electron carriers in the mitochondrial ETC and TCA cycle. Niacin supplementation has been shown to raise systemic NAD⁺ levels and improve muscle mitochondrial metabolism in humans, directly supporting mitochondrial energy production.
Vitamin B3 is essential for NAD+ synthesis, which is critical for neuronal energy metabolism, DNA repair, and survival of neurons. Severe deficiency causes pellagra with neurological manifestations including confusion and dementia. Recent reviews identify niacin as a promising therapeutic target in multiple sclerosis, Parkinson's disease, Alzheimer's disease, and ALS, operating through NAD+ replenishment and Hcar2 receptor-mediated neuroprotection.
Niacin spares tryptophan from the kynurenine pathway, preserving its availability for serotonin synthesis. It is also a precursor to NAD+, supporting energy metabolism in neurotransmitter-producing neurons. Hoffer's orthomolecular trials proposed high-dose niacin for dopamine-serotonin balance in schizophrenia. Pellagra (niacin deficiency) causes dementia confirming its necessity for CNS function.
Niacin (vitamin B3) is included in oral nutritional supplementation formulas clinically tested in picky-eating children. Picky eaters avoiding meat, fish, and nuts risk inadequate niacin intake. B3 is essential for energy metabolism and DNA repair.
Niacin (nicotinic acid) and its amide form (niacinamide) are precursors to NAD+ and NADP+, essential cofactors in cellular energy metabolism and DNA repair. Depletion during illness impairs energy recovery. Niacin supports post-illness restoration of mitochondrial function and inflammatory modulation.
Niacin (Vitamin B3) is the direct precursor to NAD+ and NADP+—coenzymes depleted in post-viral fatigue and central to mitochondrial energy production. EFSA has granted health claims for niacin in normal energy metabolism and reduction of tiredness and fatigue. The VA Long COVID guide (2023) highlights NAD+ restoration (via niacin forms including nicotinamide riboside) as a key post-viral recovery strategy.
Niacin (vitamin B3) is a precursor to NAD+, and deficiency during pregnancy has been linked to miscarriage and multiple congenital malformations via NAD+ deficiency in a landmark 2018 NEJM study. Blood niacin levels decrease during pregnancy without supplementation. An evidence-based prenatal supplement review (PMC 9275129, 2022) recommended niacin supplementation; the RDA increases to 18 mg NE/day during pregnancy.
Niacin (vitamin B3), particularly as inositol hexanicotinate, has controlled trial evidence reducing Raynaud's attack frequency and duration. An 84-day DBPC trial (n=23, primary Raynaud's) found inositol hexanicotinate significantly reduced attacks versus placebo. Alpha-tocopherol nicotinate (600 mg/day, 6 weeks) improved numbness and cold sensation in vibration-induced Raynaud's. Institutional sources including Life Extension, PeaceHealth, and Adam/SBRMC cite niacin forms as supported interventions for primary Raynaud's.
Topical niacinamide has been evaluated for rosacea in clinical studies, with evidence for anti-inflammatory activity and reduction of skin redness and blotchiness. A 2004 PubMed review confirmed demonstrable anti-inflammatory effects in rosacea. Multiple dermatology references including DermNet NZ and peer-reviewed reviews list rosacea as a studied indication for topical nicotinamide.
Niacin (nicotinic acid, vitamin B3) and its topical derivatives elevate NAD+ levels in UV-damaged skin and increase epidermal and stratum corneum thickness. A clinical study of 5% myristyl nicotinate lotion applied twice daily for 3 months confirmed these effects. Topical B3 derivatives are recognized anti-photoaging interventions in published systematic evidence reviews.
Topical niacinamide stimulates protein synthesis including collagen, stabilizes the epidermal barrier, and has been shown in controlled clinical trials to improve skin elasticity, reduce fine lines, and smooth skin texture. A 12-week split-face RCT in 50 photoaged women found significant improvements in elasticity as measured by cutometry. It also attenuates MMP-mediated collagen degradation by reducing oxidative stress.
Niacin (nicotinic acid), as a precursor to NAD+, supports cellular energy metabolism and DNA repair in UV-exposed skin. Oral nicotinamide (the amide form) is the most clinically validated form for UV photoprotection, demonstrating a 23% reduction in new non-melanoma skin cancers in an RCT. Niacinamide (nicotinamide) and niacin share NAD+ precursor activity relevant to UV-induced DNA repair.
Niacin (nicotinic acid, vitamin B3) is one of the most potent agents for lowering triglycerides, with clinical use dating to 1955. It reduces triglycerides by 20–50% at pharmacological doses (1–3 g/day) and is recognized by the AHA/ACC and AACE/ACE as a treatment option for hypertriglyceridemia.
Niacin (vitamin B3) is a vasodilator and essential coenzyme precursor (NAD+/NADP+) required for energy metabolism in rapidly dividing hair follicle cells. Deficiency (pellagra) causes hair and skin changes including alopecia. Niacinamide (the amide form) is used in scalp formulations to improve microcirculation and is often combined with other hair supplements.
Volver